APOA1 and systemic inflammatory response syndrome: Data in dogs are limited, but ApoA-1 is considered as a potential biomarker of canine systemic inflammatory response syndrome (SIRS) and sepsis acting as a negative acute-phase protein (APP) (Giunti et al., 2015; Escribano et al., 2016).